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The epidermal growth factor receptor (EGF-R) is
present on the basolateral, but not the apical,
surface of enterocytes in the human
gastrointestinal tract
R J Playford, A M Hanby, S Gschmeissner, L P Peiffer, N A Wright, T McGarrity
Abstract
Background-While it is clear that lumi-
nal epidermal growth factor (EGF) stimu-
lates repair of the damaged bowel, its
significance in maintaining normal gut
growth remains uncertain. If EGF is
important in maintaining normal gut
growth, the EGF receptor (EGF-R) should
be present on the apical (luminal) surface
in addition to the basolateral surface.
Aims/Subjects/Methods-This study exam-
ined the distribution of the EGF-R in the
epithelium throughout the human gastro-
intestinal tract using immunohisto-
chemistry, electron microscopy, and
western blotting ofbrush border prepara-
tions.
Results-Immunostaining ofthe oesopha-
gus showed circumferential EGF-R posi-
tivity in the cells of the basal portions of
the stratified squamous epithelium but
surface cells were EGF-R negative. In the
normal stomach, small intestine, and
colon, immunostaining localised the
receptor to the basolateral surface with
the apical membranes being consistently
negative. EGF-R positivity within the
small intestine appeared to be almost
entirely restricted to the proliferative
(crypt) region. Western blotting demon-
strated a 170 kDa protein in whole tissue
homogenates but not in the brush border
vesicle preparations.
Conclusions-As the EGF-R is located
only on the basolateral surfaces in the
normal adult gastrointestinal tract, the
major role of luminal EGF is probably to
stimulate repair rather than to maintain
normal gut growth.
(Gut 1996; 39: 262-266)
Keywords: cell proliferation, gut growth, localisation,
immunohistochemistry, electron microscopy, growth
factors.
Epidermal growth factor (EGF) is a potent
mitogen, which is continuously secreted into the
gut lumen by the salivary glands and the
Brunner's glands of the duodenum.' Many
studies have shown that EGF stimulates prolif-
eration ofvarious cell lines in vitro and also stim-
ulates gastrointestinal growth in whole animals
when given via the systemic circulation.2 It is
also generally accepted that luminal EGF can
stimulate repair ofthe damaged bowel.3 There is
continuing controversy, however, regarding the
role of luminal EGF in maintaining normal gut
growth in the adult human intestine. If EGF is
important in maintaining gut growth, one would
expect the EGF receptors to be present on the
apical (luminal) surfaces of the gastrointestinal
epithelium. We therefore examined the distribu-
tion of the EGF receptor (EGF-R) in the
normal human adult gastrointestinal tract using
a combination of immunohistochemistry, elec-
tron microscopy, and western blotting of brush
border preparations.
Methods
Ethical approval
This project had local ethical approval and all
subjects gave informed written consent. All
biopsy specimens were obtained during
routine endoscopy performed for clinical
reasons. Immunohistochemical and electron
microscopy analyses were performed at the
Imperial Cancer Research Fund, London and
the western blot analyses performed at The
Pennsylvania State University, USA.
Patients and collection of samples
Fresh endoscopic biopsy specimens were
obtained from the oesophagus, stomach, small
intestine, and colon of 20 histologically normal
subjects. Patients donating upper gastrointesti-
nal specimens all had a final diagnosis of non-
ulcer dyspepsia and patients donating colonic
specimens all had a final diagnosis of the irrita-
ble bowel syndrome. Biopsy forceps FB 24Q
were used to collect oesophagus, gastric, and
duodenal specimens and FG 13U forceps used
to collect colonic and ileal specimens (both
forceps obtained from Olympus Corporation,
Lake Success, NY). Ileal specimens were
obtained during colonoscopy by cannulation of
the ileocaecal valve. The average weight of
upper intestinal specimens was 9 + 1 mg and of
colonic specimens was 11 ± 1 mg. Samples for
immunohistochemistry were fixed in formal
saline, processed routinely, and embedded in
paraffin wax in the conventional manner.
Fresh sections were cut and stained with
haematoxylin and eosin to establish that no
histological abnormality was present. Samples
for western blotting were snap frozen in liquid
nitrogen and stored at -70°C until assay.
Department of
Medicine and
Therapeutics,
University of
Leicester, Leicester
R J Playford
Departments of
Histopathology
AM Hanby
N A Wright
and Electron
Microscopy
S Gschmeissner
Imperial Cancer
Research Fund,
London
Division of
Gastroenterology,
Hershey Medical
Center, Hershey, USA
L P Peiffer
T McGarrity
Correspondence to:
Professor R Playford,
Department of
Gastroenterology, Leicester
General Hospital NHS
Trust, Gwendolen Road,
Leicester LE5 4PW.
Accepted for publication
13 February 1996
262
 on 29 July 2008 gut.bmj.comDownloaded from 
Distribution of the EGF-R in normal gut
Immunohistochemistry for EGF-R
Mouse antihuman EGF-R monoclonal anti-
body was raised using purified human EGF-R,
derived from A-431 cells, as the antigen
(Triton Diagnostics, Alameda, CA, USA).
Freshly cut sections were dewaxed and incu-
bated in 100% alcohol. Endogenous peroxi-
dase activity was blocked using a 10 minute
incubation period in methanol containing
0.02% hydrogen peroxide (vol/vol). Sections
were washed in phosphate buffered saline
(PBS) and masked antigenic sites revealed by
incubating in PBS solution containing 0.04%
Nagarase (Cat no P-8038, Sigma UK) for 30
minutes. Sections were incubated in primary
mouse antihuman EGF-R monoclonal anti-
body at a final dilution of 1:25 for 35 minutes,
washed in PBS, and incubated in biotinylated
rabbit antimouse antibody (Dako E354) at a
final dilution of 1:500 to which 1:25 normal
human serum had been added. Sections were
again washed in PBS followed by incubation in
streptavidin-peroxidase at 1:500 for 30
minutes. A brown reaction product was
obtained using a peroxidase substrate
(diaminobenzidine, PBS, in addition to 0.3%
hydrogen peroxide). As a negative control, the
primary antibody was omitted from the proce-
dure. In addition, the specificity of the staining
was confirmed by taking parallel sections and
incubating in the presence of excess recombi-
nant EGF-R.
Rabbit antihuman EGF-R polyclonal antibody
12E was produced by Gullick and coworkers
using a short synthetic peptide sequence
corresponding to residues 1164-1176 of the
intracytoplasmic region of the EGF-R as the
antigen.4 Sections were prepared as described
above and incubated with the primary antibody
at a final concentration of 1/40. The second
antibody reaction consisted of incubating
sections in biotinylated swine-antirabbit anti-
body at a final concentration of 1:500 to which
1:25 normal human serum had been added. As
a negative control, the primary antibody was
omitted from the procedure. In addition, the
specificity of the staining was confirmed by
taking parallel sections and incubating in the
presence of excess recombinant EGF-R.
Electron microscopy
Fresh tissues were fixed with 4% para-
formaldehyde in 0.1 M Sorensens phosphate
buffer (pH 7.4) for eight hours at 4°C. After fix-
ation, the tissues were treated with 0.5 M
NH4Cl in phosphate buffer for four hours and
washed in buffer overnight. The tissues were
dehydrated in a graded series of methanol con-
centrations (50, 70, 80, 90% and absolute
methanol, each for 10 minutes) at progressively
lower temperatures and infiltrated with Lowicryl
HM20 at -35°C. The resin was polymerised by
ultraviolet light for 48 hours at - 50°C.
For immunogold studies, ultrathin sections
were mounted on carbon coated grids and
labelled as follows. After five minutes on a drop
of PBS and one hour preincubation on 10%
normal goat serum, 5% bovine serum albumin
(BSA), and 5% ovalbumin in PBS, the grids
were transferred onto drops of rabbit anti-
human EGF-R antiserum, 1 2E (1:40 dilution in
PBS containing 0.5% BSA, 050/o ovalbumin,
and 1% normal goat serum) for eight hours at
4°C. Sections were washed three times over a 15
minute period with PBS containing 0.5% BSA,
0.5% ovalbumin, and 1% normal goat serum
followed by incubation with immunogold con-
jugates (1:100 goat antirabbit IgG, 5 nm gold)
for two hours. After rinsing in PBS (3Xfive
minutes) and distilled water (3Xfive minutes),
the sections were silver enhanced for four
minutes at room temperature using an Intense
M Silver Enhancement Kit (Amersham, UK)
before contrasting with uranyl acetate and lead
citrate. Sections were then examined using a
Zeiss 10 C electron microscope. As a negative
control, the primary antibody was omitted from
the procedure.
Western blotting
Background to method-to determine if the
apical membranes contained EGF-R, purified
brush border vesicles were prepared and
probed for the presence of EGF-R protein
using western blotting. The quality of the
brush border preparations was determined by
following changes in the specific activity of
alkaline phosphatase activity, whose expression
is restricted to the apical membranes.5 Two
rabbit polyclonal antibodies were used for
these studies; 12E, which had also been used
for the immunohistochemical localisation
studies described above and a further affinity
purified rabbit-antihuman EGF-R raised
against a synthetic peptide corresponding to
residues 1005 to 1016 of the human EGF
receptor protein (EGFR-1005, Santa Cruz
Biotechnology, Santa Cruz, CA).
Preparation of brush border vesicles-brush
border preparations were made from duodenal
and ileal tissue using the protocol described by
Simpson,6 which is a modification of the
original technique of Kessler.5 In these
methods, the microvesicle samples are purified
from potentially contaminating intracellular
organelles by incorporating a centrifugation
step in which MgCl2 had been pre-added to
the diluent (which causes the organelles, but
not the brush border vesicles, to precipitate).
This protocol produces apical membrane
preparations that are essentially free from con-
taminating organelles as judged by electron
microscopy and marker enzymes.5 6 Aliquots
of the initial tissue homogenate and the final
microvesicle preparations were assayed for
total protein7 and alkaline phosphatase activity
(Sigma alkaline phosphatase assay kit, St
Louis, USA).
Western blotting-this was performed using
one dimensional SDS-PAGE electrophoresis.
Eighty pug of sample protein were loaded into
each lane of a 7.5% SDS-PAGE gel. Samples
consisted of whole tissue homogenate,
microvesicle preparations, and prestained
molecular weight markers. After electro-
phoresis, the proteins were electroblotted onto
nitrocellulose paper and stained with Ponceau
S to confirm complete transfer and loading
263
 on 29 July 2008 gut.bmj.comDownloaded from 
Playford, Hanby, Gschmeissner, Peiffer, Wright, McGamity
efficiency. The nitrocellulose filters were then
destained prior to incubation in a blocking
solution for 30 minutes (5% non-fat dry milk,
0.5 M NaCl, 0.02M TRIS pH 7.4, 0O1%
TWEEN 20). Filters were then incubated with
primary antibodies (E12 or EGF-R 10050,
each at 5 ,ug/ml) for 45 minutes and washed
three times with TBS (containing 005%
TWEEN 20). Blots were then incubated with
horseradish peroxidase conjugated goat
antirabbit antibody diluted 1:1000 in 5% non-
fat dry milk for 30 minutes. Filters were then
washed three times in TBS, 0.05% TWEEN
Figure 1: Immunohistochemical localisation of the EGF-R using rabbit antihuman
polyclonal antibody 12E. EGF-R positivity was visualised using DAB, giving a brown
reaction product. In the oesophagus, weak EGF-R positivity is seen circumferentially in
cells of the basal region of the stratified squamous epithelium but EGF-R positivity
disappears as the cells approach the luminal surface (A, original magnification X400). In
the stomach, EGF-R positivity was seen on the basolateral surfaces on surface, parietal,
and mucus neck cells with particularly strong staining on the parietal cells (B, original
magnification X400). In the small intestine, EGF-R positivity was restricted to the
basolateral membranes of the proliferative (crypt) region and the goblet cells of the villi,
with little or no positivity on the villus enterocytes (C, original magnification X250). In the
colon, EGF-R positivity was seen on the basolateral surfaces of cells in all regions of the
crypts with relatively weak staining of the basolateral membranes of the surface colonocytes.(D, original magnification X400.)
20 followed by one wash in TBS (each wash
for five minutes). The presence of the EGF-R
proteins was then visualised using the ECL
(chemiluminescence) system (Amersham,
UK) by incubating in the ECL reagents for one
minute as recommended by the manufacturer.
All assays were performed in quadruplicate.
To determine the specificity of the reaction,
western blots were performed in which the
primary antibody had been pre-incubated in
excess recombinant EGF-R (kindly donated
byW Gullick, ICRF).
Results
Immunohistochemistry and electron microscopy
In the oesophagus, weak membrane localised
EGF-R positivity was seen circumferentially in
the deeper portions of the stratified squamous
epithelium but surface cells were negative (Fig
1A). The gastric body and antrum epithelium
showed EGF-R-like immunoreactivity in the
basolateral membranes with particularly strong
staining of the parietal cells. Surface mem-
branes were consistently negative (Fig 1B).
Duodenal and ileal tissue showed EGF-R-like
positivity on the basolateral surfaces of the
crypt regions (Fig 1 C) and on the goblet cells
of the villi, however, the enterocytes on the villi
appeared to be EGF-R negative. Colonic
mucosa showed EGF-R-like positivity in a
basolateral distribution in all regions of the
crypts (Fig 1D). Distribution of EGF-R posi-
tivity visualised using electron microscopy gave
similar results (Fig 2). Therefore, the
apical/surface membranes abutting the intesti-
nal lumen were consistently negative through-
out the gastrointestinal tract. The negative
control and slides in which excess recombinant
EGF-R had been added showed no staining,
confirming the specificity of the reaction.
Western blotting
On each occasion, brush border preparations
showed a pronounced increase in alkaline
phosphatase activity (typical specific activity of
alkaline phosphatase in ileal whole tissue
homogenate was 0O1 U/mg protein compared
with 0.9 U/mg protein in brush border
preparations). The major band seen in duo-
denal and ileal whole tissue homogenates had
an apparent molecular weight of approximately
170 kDa, with some fainter smaller bands
(with apparent molecular weights of approxi-
mately 150 and 100 kDa) being inconsistently
seen in whole tissue homogenates of ileal
preparations. Brush border vesicle prepara-
tions from these tissues were consistently neg-
ative (Fig 3). Importantly, no bands were seen
in any of the lanes in parallel western blots in
which the primary antibody had been pre-
incubated in excess recombinant EGF-R.
Discussion
Using a variety of different techniques, we have
examined the distribution of the EGF-R in
the human gastrointestinal tract. All results
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Figure 2: Electron microscopy ofgastric body showing
EGF-R positivity (visualised using gold tagged antibody)
is present on the basolateral but not the apical (luminal, L)
membranes ofgastric glands. This is particularly well seen
on the arrowed cell. Original magnification X6000.
suggest that, in the normal human adult gut,
the apical/surface membranes abutting the
intestinal lumen do not express EGF-R.
We used two different antibodies (one
monoclonal and one polyclonal) to examine
the distribution of the EGF-R by immuno-
histochemistry to decrease the possibility of
false EGF-R-like positivity. For all regions of
the gastrointestinal tract, results were consist-
ent between the two. The major form ofEGF-
R found in tissue homogenates of duodenum
and ileum had an apparent molecular weight of
about 170 kDa, although fainter bands were
sometimes seen at approximately 150 and 100
kDa, probably representing partial degradation
products of the EGF-R.
EGF is a 53 amino acid peptide (molecular
weight 6400), which is secreted into the
gastrointestinal lumen from the salivary
glands and Brunner's glands of the duode-
num.' Gastric juice concentrations of EGF
are about 500 ng/1,8 sufficient to stimulate
growth of epithelial cells in vitro. The concen-
tration of luminal EGF in the small and large
intestine is less certain, but probably varies
according to the presence or absence of
ingested proteins as EGF is susceptible to
digestion by pancreatic proteases.9 The
sequence and structure of the EGF-R is well
characterised and consists of an intracellular
domain (with tyrosine kinase activity), a
single transmembrane region, and an extra-
cellular domain with a single ligand binding
site. Although many studies have shown that
EGF is a potent mitogen for gastrointestinal
tissue in vitro and when given systemically in
vivo,2 there is continuing debate as to its role
Figure 3: Western blots of tissue homogenates and
microvillus preparations using rabbit antihuman EGF-R
antibody 12E. Eighty micrograms ofprotein were loaded
per lane in the following distribution; whole tissue
homogenate (lane 1) and microvillus preparation ofduodenum (lane 2), and whole tissue homogenate (lane 3)
and microvillus preparations of ileum (lane 4). Arrows
show the position ofprotein markers of molecular weights
220 and 90 kDa. Bands corresponding to full length
EGF-R are seen in whole tissue homogenates of
duodenum and ileum, but not in the microvillus
preparations suggesting that the distribution ofEGF-R is
limited to basolateral membranes. Note that ileal whole
tissue homogenates (lane 3) also showed inconsistent bands
of approximately 150 and 100 kDa, probably
corresponding to a partial degradedform ofEGF-R. No
bands were seen in western blots performed in parallel in
which the antibody had been pre-incubated with
recombinant EGF-R.
in the normal gastrointestinal tract. If luminal
EGF is important in maintaining normal
gastrointestinal growth (or influencing gastric
acid secretion, or both), one would expect the
EGF-R to be present on the apical (luminal)
membranes as the tight junctions of the
intestinal epithelium probably prevents para-
cellular translocation of the peptide under
normal circumstances.
Most ofthe previous studies in this area have
examined the distribution of the EGF-R in
animal models, particularly the rat. A paper by
Thompson and coworkers suggests that, in
the adult rat, the EGF-R is restricted to the
basolateral membranes.10 However, species
differences may exist as Kelly and coworkers
reported that EGF-Rs are present on the apical
membranes of the pig intestine (using the tech-
nique of autoradiographic localisation'1l).
There have been few equivalent studies per-
formed in humans and these have mainly
focused on the distribution of the EGF-R in
the oesophagus and stomach. Using immuno-
histochemical staining, Jankowski and co-
workers reported EGF-R-like positivity in a
circumferential distribution in the basal por-
tion of the stratified squamous epithelium of
the oesophagus,'2 in keeping with our results.
However, in contrast with our findings, they
found that the EGF-R was present on the
apical and basolateral membranes of the
normal human stomach.'3 A similar apical dis-
tribution has been also reported in the adult
stomach and colon by Hormi and Lehy.14
Reasons for these differences are unclear,
although the methods used by both groups
were restricted to immunohistochemical local-
isation and the antibodies used by each group
(Ab-1 by Jankowski, and Ab-4 by Hormi and
Lehy, both monoclonal IgG's obtained from
Oncogene Science, Manhaset, NY, USA) were
different from the two used in this study. A
different monoclonal antibody (528IgG) was
used by Mori and coworkers to examine the
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distribution of the EGF-R in the human
stomach using the technique of electron
microscopy. They reported that the EGF-R
was restricted to the basolateral membranes of
parietal cells,'5 in keeping with our findings.
However, caution has to be shown in interpret-
ing the results from this study as the 'appar-
ently normal gastric fragments' were obtained
from patients having gastric resections for
gastric carcinoma. It was because of these
apparently conflicting results that, in contrast
to all of these other studies, we decided to use
several different techniques and antibodies
(both monoclonal and polyclonal) to examine
the distribution of the EGF-R in detail.
Our confirmation that the EGF-R positivity
was restricted to basolateral membranes
suggests that the role of luminal EGF in the
adult gut is to act as a 'luminal surveillance pep-
tide'; readily available to stimulate repair at sites
of injury (when it can reach its receptor), but of
comparatively minor importance in maintaining
gut growth.16 However, it is important to note
that the EGF-R also binds transforming growth
factor cx, amphiregulin, and heparin binding
EGF. Our findings that the EGF-R is present
on the basolateral surfaces of the parietal cells of
the stomach and the proliferative (crypt) regions
of the small and large intestine suggests that one
or more ofthese other ligands may be important
in controlling acid secretion and proliferation of
the gastrointestinal tract.
It will be of interest to extend these studies to
examine the distribution of the EGF-R in the
neonatal or adult damaged bowel as animal
studies suggest that, in these conditions, lumi-
nal EGF is capable of stimulating gut growth
and repair. This may be because of an altered
distribution of the EGF-R, or alternatively, that
the increased permeability of the neonatal or
damaged bowel allows luminal EGF to reach
its receptor on the basolateral membranes.
We thank the Medical Research Council and the Wellcome
Trust for funding.
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